Morgan Stanley Initiates Coverage On Centessa Pharmaceuticals with Overweight Rating, Announces Price Target of $37
Morgan Stanley analyst Matthew Harrison initiates coverage on Centessa Pharmaceuticals (NASDAQ:CNTA) with a Overweight rating and announces Price Target of $37.
Goldman Sachs Initiates Coverage On Centessa Pharmaceuticals with Buy Rating, Announces Price Target of $42
Goldman Sachs analyst Salveen Richter initiates coverage on Centessa Pharmaceuticals (NASDAQ:CNTA) with a Buy rating and announces Price Target of $42.
Morgan Stanley Initiates Coverage On Centessa Pharmaceuticals with Overweight Rating, Announces Price Target of $37
Morgan Stanley analyst Matthew Harrison initiates coverage on Centessa Pharmaceuticals (NASDAQ:CNTA) with a Overweight rating and announces Price Target of $37.
Jefferies Initiates Coverage On Centessa Pharmaceuticals with Buy Rating, Announces Price Target of $35
Jefferies analyst Eun Yang initiates coverage on Centessa Pharmaceuticals (NASDAQ:CNTA) with a Buy rating and announces Price Target of $35.
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries.
The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 14)
60 Biggest Movers From Yesterday
Gainers
RAPT Therapeutics, Inc. (NASDAQ: RAPT) shares jumped 115.5% to settle at $40.02 on Monday as the company announced topline results from its Phase 1b trial of RPT193 as monotherapy for moderate-to-severe atopic dermatitis (AD).
The Daily Biotech Pulse: Merck Completes Organon Spin-Off, Auris Repositions As RNA Therapeutic Company With Trasir Purchase, Replimune’s Readout
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 2)